Myriad Genetics (MYGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.25
- Estimate
- -$0.06
- Surprise
- -332.7%
- Score at report (before → after)
- 4.7 → 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Myriad Genetics (MYGN) reported a wider loss than forecast — adjusted EPS of -$0.25 against the -$0.06 estimate (a 332.7% shortfall). TrendMatrix's engine moved from Sell (4.7/10) to Hold at 5.3/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MYGN Sell at 4.1/10.
1 of the last 4 quarters beat the estimate; this quarter's -332.7% surprise compares with a +20.2% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Target reached (-35.1% upside)
- Quality below floor (3.6 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (5 sells, 0.12% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.02
- Stop
- $5.60
Risk check: RSI 78 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
MYGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $575.8M
- P/E (fwd)
- -10.2
- 52-week range
- $2.74–$8.50
- Off 52-week high
- 29.2%
- RSI (14)
- 78
- Volume vs avg
- 0.48×
- Score today
- 4.1/10